GARANGER, Elisabeth; MIGNET, Nathalie; PICHON, Chantal; ROLS, Marie-Pierre; SANCEY, Lucie

doi:10.1016/j.ijpharm.2023.122928

Laboratoire de Chimie des Polymères Organiques [LCPO]
Team 3 LCPO : Polymer Self-Assembly & Life Sciences

MIGNET, Nathalie
Unité de Technologies Chimiques et Biologiques pour la Santé [UTCBS - UM 4 (UMR 8258 / U1267)]

PICHON, Chantal
Université d'Orléans [UO]

Idioma

Article de revue

Este ítem está publicado en

International Journal of Pharmaceutics. 2023-05-10, vol. 638, p. 122928

Resumen en inglés

The field of nanomedicine has reached a milestone since the approval of Patisiran, the first ever-approved siRNA drug designed to treat transthyretin (TTR) amyloidosis. The great success of Corminaty and Spikevax messenger RNA (mRNA)-based vaccines against COVID-19 has really brought to light how potent nanomedicine could be. Today, stakeholders are getting more confident in the benefits of nanomedicine for diagnosis, treatment, vaccination, and research related to different types of diseases. For the years to come, it is becoming clear that we need a multidisciplinary approach to achieve a rational design of nanomedicine. Impelling the meeting and discussions of academic and private actors from different disciplines is one of the goals of the French Society for Nanomedicine (SFNano).< Leer menos

Palabras clave en inglés

Nanomedicine

Drug Delivery Systems

mRNA-based vaccines

siRNA drugs

URI

https://oskar-bordeaux.fr/handle/20.500.12278/182350

DOI

http://dx.doi.org/10.1016/j.ijpharm.2023.122928

Centros de investigación

Laboratoire de Chimie des Polymères Organiques (LCPO) - UMR 5629

Ver/Abrir

Metadatos

Compartir este ítem

Licencia de uso del documento

A special issue dedicated to the 2021 meeting of the French Society for Nanomedicine.

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación